Chargement en cours...
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal regulator of osteoclastic bone resorption. Postmenopausal osteoporosis (PMO) is a systemic skeletal disease assoc...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2011
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3264422/ https://ncbi.nlm.nih.gov/pubmed/22279412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S7727 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|